The bisphosphonate incadronate for bone metastases of breast cancer

被引：5

作者：

Koizumi M. ^{[1
]}

Kobayashi M. ^{[2
]}

Furukawa M. ^{[2
]}

Yamashita T. ^{[2
]}

Ogata E. ^{[3
]}

机构：

[1] Department of Nuclear Medicine, Cancer Institute Hospital, 1-37-1 Kami-Ikebukuro, Toshima-ku

[2] Department of Radiotherapy, Cancer Institute Hospital, Tokyo

[3] Department of Internal Medicine, Cancer Institute Hospital, Tokyo

来源：

International Journal of Clinical Oncology | 2000年 / 5卷 / 4期

关键词：

Bisphosphonate; Bone Metabolic markers; Bone metastasis; Breast cancer; Tumor marker;

D O I：

10.1007/PL00012044

中图分类号：

学科分类号：

摘要：

Background. Bisphosphonates are bone resorption inhibitors which are effective in the treatment of diseases of increased bone turnover, such as hypercalcemia of malignancy and osteolytic bone metastasis. The safety and efficacy of incadronate, a third-generation bisphosphonate, were evaluated in breast cancer patients with bone metastases. Methods. Fifteen breast cancer patients with bone metastasis were enrolled. Incadronate's safety, its effectiveness in relieving bone pain, and its effects on bone metabolic markers and a tumor marker were assessed in 8 patients treated with a 10-mg IV infusion once a week for 5 weeks (10mg x 5), 3 patients treated with a single 20-mg IV infusion (20mg x 1), and 4 patients treated with a 20-mg IV infusion once a week for 5 weeks (20mg x 5). Pain assessment was performed only in the patients with the repeated infusion regimens. Results. All incadronate treatment regimens were administered without any serious adverse reactions. Minimal fever was noted in 6 patients, but it subsided without any treatment. Incadronate relieved bone pain in 10 of the 12 patients who received repeated infusions. Levels of bone resorption markers dropped transiently, but the decreases in the individual markers of bone resorption varied. Levels of bone formation markers did not change significantly. Levels of a tumor marker specific to breast cancer, carbohydrate antigen (CA)15-3 decreased in patients whose metastases were limited to bone. Conclusion. The third-generation bisphosphonate, incadronate, was administered safely at dosages of up to 20mg once a week for 5 weeks. Incadronate reduced bone pain, bone resorption marker levels, and CA15-3 tumor marker levels in breast cancer patients with bone metastases.

引用

页码：241 / 246

页数：5

共 16 条

[11]

Tong D., Gillick L., Hendrickson F.R., The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group, Cancer, 50, pp. 893-899, (1982)

[12]

Garnero P., Gineyts E., Arbault P., Et al., Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion, J Bone Miner Res, 10, pp. 641-649, (1995)

[13]

Coleman R.E., Purohit O.P., Vinholes J.J., Zekri J., High dose pamidronate: Clinical and biochemical effects in metastatic bone disease, Cancer, 80, pp. 1686-1690, (1997)

[14]

Garnero P., Shin W.J., Gineyts E., Et al., Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment, J Clin Endocrinol Metab, 79, pp. 1693-1700, (1994)

[15]

Koizumi M., Takahashi S., Ogata E., Bone metabolic marker in bone metastasis of breast cancer, Int J Clin Oncol, 4, pp. 331-337, (1999)

[16]

Koizumi M., Maeda H., Yoshimura K., Et al., Dissociation of bone formation markers in bone metastasis of prostate cancer, Br J Cancer, 75, pp. 1601-1604, (1997)

← 1 2 →